| NF-kappa B signaling pathway |
1.79 |
9.94e-2 |
90/104 (86.54%) |
CCL4;CXCL12;RELB;...
|
| Mismatch repair |
1.57 |
5.92e-1 |
22/23 (95.65%) |
PCNA;LIG1;MLH1;...
|
| DNA replication |
1.55 |
5.08e-1 |
34/36 (94.44%) |
PCNA;LIG1;RFC4;...
|
| Pentose phosphate pathway |
1.51 |
5.16e-1 |
25/30 (83.33%) |
FBP1;PFKP;PGD;...
|
| Arginine biosynthesis |
1.49 |
4.81e-1 |
17/22 (77.27%) |
ARG1;ASS1;GLUL
|
| Pyrimidine metabolism |
1.48 |
4.49e-1 |
40/56 (71.43%) |
TYMS;CDA;NT5E;...
|
| Protein export |
1.40 |
7.33e-1 |
17/23 (73.91%) |
SEC61B;SRP72;SRP14;...
|
| Nicotinate and nicotinamide metabolism |
1.40 |
6.59e-1 |
25/35 (71.43%) |
CD38;NT5E;SIRT3;...
|
| Nucleotide excision repair |
1.40 |
5.87e-1 |
40/47 (85.11%) |
PCNA;RAD23B;LIG1;...
|
| Steroid hormone biosynthesis |
1.39 |
5.73e-1 |
43/61 (70.49%) |
CYP3A4;CYP2E1;CYP3A5;...
|
| African trypanosomiasis |
1.37 |
5.85e-1 |
32/37 (86.49%) |
HBB;IDO1;PLCB3;...
|
| Mucin type O-glycan biosynthesis |
1.37 |
5.41e-1 |
20/36 (55.56%) |
GALNT12;GALNT10;ST6GALNAC4;...
|
| Mitophagy |
1.34 |
6.10e-1 |
56/68 (82.35%) |
BNIP3L;TP53;RRAS2;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
1.33 |
6.27e-1 |
62/70 (88.57%) |
CCL5;CDC42;JUN;...
|
| Ferroptosis |
1.32 |
6.11e-1 |
36/41 (87.8%) |
FTH1;TP53;ACSL5;...
|
| Pathways in cancer |
1.10 |
7.43e-1 |
474/531 (89.27%) |
ESR1;VEGFA;EGLN3;...
|
| Other types of O-glycan biosynthesis |
1.10 |
7.36e-1 |
29/47 (61.7%) |
GALNT12;GALNT10;ST6GAL1;...
|
| RNA transport |
1.10 |
7.33e-1 |
128/186 (68.82%) |
EEF1A2;CASC3;EIF3H;...
|
| Cholesterol metabolism |
1.10 |
7.21e-1 |
44/50 (88%) |
LDLR;STAR;APOA2;...
|
| Allograft rejection |
1.09 |
7.21e-1 |
32/38 (84.21%) |
CD40;HLA-DOB;HLA-B;...
|
| Cytokine-cytokine receptor interaction |
1.09 |
7.11e-1 |
246/295 (83.39%) |
CCL4;CXCL12;CCL5;...
|
| Renal cell carcinoma |
1.09 |
7.02e-1 |
68/69 (98.55%) |
VEGFA;EGLN3;CDC42;...
|
| AGE-RAGE signaling pathway in diabetic complications |
1.09 |
6.94e-1 |
97/100 (97%) |
VEGFA;CDC42;COL3A1;...
|
| RNA polymerase |
1.09 |
6.89e-1 |
23/31 (74.19%) |
POLR1D;POLR2G;POLR2L;...
|
| Parkinson disease |
1.08 |
6.92e-1 |
176/249 (70.68%) |
GNAI1;SNCA;KIF5C;...
|
| Chemokine signaling pathway |
1.08 |
6.89e-1 |
163/192 (84.9%) |
CCL4;GNAI1;CXCL12;...
|
| Primary immunodeficiency |
1.07 |
7.06e-1 |
33/38 (86.84%) |
CD40;CD8A;DCLRE1C;...
|
| MicroRNAs in cancer |
1.07 |
7.10e-1 |
146/310 (47.1%) |
VEGFA;MARCKS;TP53;...
|
| Serotonergic synapse |
1.06 |
7.29e-1 |
97/114 (85.09%) |
ALOX5;GNAI1;PLCB3;...
|
| Cellular senescence |
1.06 |
7.17e-1 |
139/156 (89.1%) |
TP53;RRAS2;NFATC3;...
|
| Osteoclast differentiation |
-1.23 |
5.23e-1 |
117/127 (92.13%) |
LCP2;NOX1;IFNGR1;...
|
| Neutrophil extracellular trap formation |
-1.24 |
5.22e-1 |
101/189 (53.44%) |
CLEC7A;NCF4;FPR2;...
|
| Endometrial cancer |
-1.24 |
5.13e-1 |
56/58 (96.55%) |
AKT3;GSK3B;PIK3CA;...
|
| Aminoacyl-tRNA biosynthesis |
-1.24 |
5.09e-1 |
15/66 (22.73%) |
SARS2;IARS2;GATB;...
|
| Pyruvate metabolism |
-1.25 |
5.05e-1 |
41/47 (87.23%) |
GRHPR;ACAT1;ACYP2;...
|
| Synthesis and degradation of ketone bodies |
-1.25 |
5.16e-1 |
9/10 (90%) |
ACAT1;HMGCS1;ACAT2;...
|
| Colorectal cancer |
-1.25 |
5.23e-1 |
84/86 (97.67%) |
AKT3;GSK3B;PMAIP1;...
|
| Breast cancer |
-1.25 |
5.24e-1 |
119/147 (80.95%) |
AKT3;GSK3B;PIK3CA;...
|
| Arginine and proline metabolism |
-1.26 |
5.28e-1 |
39/50 (78%) |
LAP3;SMS;GAMT;...
|
| Cell adhesion molecules |
-1.26 |
5.25e-1 |
118/148 (79.73%) |
SELPLG;ICAM2;PTPRF;...
|
| Hepatitis C |
-1.27 |
5.25e-1 |
139/157 (88.54%) |
IKBKE;CLDN8;IRF3;...
|
| Chronic myeloid leukemia |
-1.27 |
5.29e-1 |
72/76 (94.74%) |
RUNX1;AKT3;PIK3CA;...
|
| Staphylococcus aureus infection |
-1.35 |
5.13e-1 |
72/95 (75.79%) |
C1QB;KRT14;HLA-DRA;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.35 |
5.27e-1 |
172/193 (89.12%) |
MAPKAPK2;PPP3CA;IKBKE;...
|
| Pancreatic secretion |
-1.36 |
5.26e-1 |
87/102 (85.29%) |
CTRB2;CELA2A;PNLIPRP2;...
|
| Regulation of lipolysis in adipocytes |
-1.37 |
4.95e-1 |
52/55 (94.55%) |
NPR1;ADCY2;ADCY9;...
|
| Legionellosis |
-1.38 |
4.85e-1 |
51/57 (89.47%) |
HSPA1A;RAB1A;TLR5;...
|
| alpha-Linolenic acid metabolism |
-1.38 |
5.09e-1 |
17/25 (68%) |
ACOX1;PLA2G4A;PLA2G10;...
|
| Systemic lupus erythematosus |
-1.38 |
5.27e-1 |
45/135 (33.33%) |
FCGR2A;HLA-DRB1;HLA-DPB1;...
|
| Glycerolipid metabolism |
-1.44 |
5.28e-1 |
44/61 (72.13%) |
PLPP1;DGKQ;PNLIPRP2;...
|
| Salivary secretion |
-1.47 |
4.51e-1 |
76/93 (81.72%) |
ATP2B2;CST5;GNAQ;...
|
| Pathogenic Escherichia coli infection |
-1.48 |
4.89e-1 |
152/197 (77.16%) |
NFKBIB;ACTR2;NCKAP1;...
|
| Propanoate metabolism |
-1.50 |
4.66e-1 |
30/34 (88.24%) |
ECHDC1;PCCA;ACAT1;...
|
| Vasopressin-regulated water reabsorption |
-1.50 |
5.12e-1 |
40/44 (90.91%) |
ADCY9;DYNC1LI1;STX4;...
|
| Mineral absorption |
-1.56 |
3.92e-1 |
48/60 (80%) |
ATP2B3;CYBRD1;SLC26A3;...
|
| Ether lipid metabolism |
-1.56 |
4.68e-1 |
32/49 (65.31%) |
PLPP1;PLA2G7;PLA2G4A;...
|
| Fatty acid elongation |
-1.59 |
4.54e-1 |
19/27 (70.37%) |
MECR;ECHS1;ELOVL4;...
|
| Valine, leucine and isoleucine degradation |
-1.66 |
2.79e-1 |
42/48 (87.5%) |
BCAT2;PCCA;AACS;...
|
| Glycerophospholipid metabolism |
-1.72 |
2.33e-1 |
71/98 (72.45%) |
PLPP1;DGKQ;LPIN1;...
|
| Aldosterone-regulated sodium reabsorption |
-1.81 |
1.40e-1 |
34/37 (91.89%) |
ATP1B2;ATP1B1;HSD11B2;...
|
